Skip to main content
Triangle logo TriangleGet started

Telisotuzumab Adizutecan (NCT07023289)

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease: a one-minute explainerNCT070232891 min

Telisotuzumab Adizutecan trial for Colorectal Cancer (NCT07023289). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with colon or rectal adenocarcinoma, no cancer visible on scans, but positive circulating tumor DNA after surgery and qualifying chemotherapy. At least three months of platinum-doublet treatment and surgical tissue for personalized DNA testing are required.

The idea: telisotuzumab adizutecan carries a DNA-replication-blocking payload to cells bearing c-Met. The study compares this intravenous drug alone with usual care. Researchers track recurrence, survival and side effects. Positive tumor-DNA testing must meet specified timing limits after treatment.

This phase 2 study plans 140 patients. AbbVie sponsors twenty-one recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.